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Abstract
Introduction
The purpose of the work is to see if there is a dosimetric benefit to using one treatment
modality over another when treating centrally located brain tumors. These modalities include
helical tomotherapy, non-coplanar VMAT, and coplanar VMAT.
Methods
Thirty plans were created from ten previously treated patient’s datasets. All patients were
planned using a simultaneously integrated boost with a PTV54 and PTV 60. The conformity
index and homogeneity index were compared for targets. Dose maximums and means were
compared for critical structures between the plans and modalities.
Results
A significant difference was found for the conformity index for 5400 cGy where helical
tomotherapy was the furthest from 1 by more than 10%. For 95% of the higher prescription dose
of 6000cGy (5700cGy), the mean conformity index was significantly closer to 1 for helical
tomotherapy by more than 20% compared to the other two modalities. Helical Tomotherapy had
a significantly higher dose to both lenses and both optic nerves as well as a higher mean dose for
the brain stem and normal brain subtracting the PTVs. Helical tomotherapy met all dose
constraints for all plans where coplanar VMAT and non-coplanar VMAT did not for two patients
where the brainstem was within 3mm of the PTV60.
Conclusion
For centrally located brain tumors, helical tomotherapy was able to meet all constraints
and had a higher CI for 95% of higher target volume. Non-coplanar and coplanar VMAT’s dose
to normal structures were comparable and lower than helical tomotherapy but were unable to
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meet brain stem dose constraints for 2 patients. While all modalities have proven acceptable and
useful in treating centrally located brain tumors, the author recommends using HT.

Introduction
According to Ostrom, there should have been an estimated 83,830 cases of central
nervous system cancer diagnosed in the year 2020. Roughly thirty percent of those cases were
expected to be malignant.1 Malignant gliomas are tumors that arise from glial cells and are the
most common central nervous system tumor. They account for an estimated 20,000 cases per
year.2 For malignant brain tumors, the median survival length of patients after diagnosis can
range from 8 months for patients diagnosed with glioblastoma, to 139 months for patient
diagnosed with malignant pituitary cancers.1 The five year relative survival rate for patients
diagnosed with primary malignant brain and other central nervous system (CNS) tumors is
23.5%. The five year relative survival rate for patients diagnosed with non-malignant brain and
CNS tumors is 82.4%.1
CNS tumors are typically treated with medical therapy, surgery, radiation therapy or a
combination of those depending on type of tumor and symptoms. Medical therapy includes the
use of steroids like dexamethasone and some chemotherapy agents such as temozolomide and
bevacizumab.3 For emergent symptoms, surgical resection or a placement of a shunt (a passage
or tube made to allow fluid to move and drain) is often necessary. Steroids are also utilized, such
as dexamethasone.4
Treatment options vary for gliomas depending on the grade of the tumor. For grade I
tumors, surgery alone is the standard. Current practices for grade II include a safe gross total
resection including close follow up with radiologic scans. The goal for treatment of grade III
and grade IV tumors include a safe gross total resection, concomitant chemoradiation, and follow
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up with radiologic scans.2 For high grade gliomas, according to Khan, the standard radiation
fractionation is “45 to 50 Gy to a clinical target including all surrounding postoperative flair
signal plus a 2-cm margin” followed by a boost up to 60 Gy.4 Other sources say for grade III and
IV gliomas, the standard Stupp protocol is radiotherapy and concomitant chemoradiation using a
total of 60 Gray with 2 Gray per fraction with temozolomide.2
Considerations should be taken into account when delivering doses of radiation this high
next to critical structures and organs at risk (OAR). There are some serial structures in the brain
that need to be evaluated as a max point dose in addition to volumetric dose.5 Intensity
modulated radiation therapy (IMRT) is more beneficial when the proximity of the targets are
close to radiosensitive OARs such as the optic chiasm, optic nerves, and brainstem.6 The OAR
immediately around centrally located brain tumors are the brain stem, cochleas, hippocampus,
lenses of the eyes, optic chiasm, optic nerves, and spinal cord.5
To minimize OAR side effects, the normal brain should be kept to below a maximum
dose of 72 Gy for a less than 5% chance of side effects. The entire brain stem should have a
maximum dose of below 54Gy. Between 1-10cc can go up as high as 59 Gy in the brain stem.
Cochleas should be kept to a mean dose of less than or equal to 45 Gy. The optic nerve and
chiasm should have a maximum dose of less than 54 Gy. The spinal cord should also be kept
below 50 Gy.7 Due to the high mortality rate for glioma’s, compromising coverage for
hippocampus protection is not recommended.8 Each lens should be kept below 10 Gy, ideally
less than 6Gy.9
The location of the tumor and these organs needs to be mapped out in a radiation
simulation.4 A simulation should include the use of computed tomography (CT) treatment
planning.4 The patient should be lying supine with immobilization of the head. This will include

4

an aquaplast mask with a custom head holder to help prevent the head from moving while
delivering treatment. The mask and head holder also help aid in reproducibility.4,5
Magnetic resonance imaging (MRI) has proven to be extremely useful in defining some
of the OARs, as well as delineating the tumors and surrounding enhanced abnormalities for the
clinical target volume (CTV). The CTV includes the entire tumor and the invisible microscopic
disease. It can be estimated only clinically and that is why it is named CTV.4 MRI is the gold
standard for imaging both benign and malignant CNS tumors. T1 and T2 weighted images are
registered and fused with the CT scan done for simulation. Physicians use MRIs to create the
gross tumor volume and the clinical target volume.4,5
There are a number of different types of radiation treatment modalities that have been
used to treat brain tumors: fixed field step and shoot intensity modulated radiation therapy
(IMRT), conventional (2D), 3D conformal radiotherapy, coplanar volumetric modulated arc
therapy (cVMAT), non-coplanar volumetric modulated art therapy (nVMAT), helical
tomotherapy (HT), stereotactic radiotherapy (SRT), stereotactic radiosurgery (SRS), as well as
radioactive implants. Many of these techniques can achieve acceptable plans and have been
researched in other literature.4,9–11
Previous studies compare cVMAT, nVMAT, and fixed field static field IMRT.12–14 One
study suggests that nVMATs help reduce dose to certain OARs when compared to cVMAT, such
as the hippocampus. The study found the mean dose was 6.8 Gy for nVMAT when compared to
10.8 Gy for cVMAT. The dose threshold this study used for the hippocampus was 7.3 Gy.14
Another study showed that cVMAT and nVMAT didn’t affect organs at risk greatly in
glioblastoma radiotherapy when compared to each other. However, it showed that either type of
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VMAT had statistically significant reduction in the mean dose to the optic chiasm and a
reduction in the amount of MUs used when compared to step and shoot IMRT.12
Additional studies compare cVMATs, HT, and fixed field static field IMRT.9,15 One
study states that HT had improved conformity and lower dose to OARs when compared to
cVMAT and static field IMRT in treatment of high grade gliomas. The study showed similar
planned treatment volume (PTV) coverage between cVMAT, HT, and IMRT. The author said
that HT has a better homogeneity index (HI) when compared to IMRT and cVMAT but that it
was not statistically significant. The conformity index (CI) of HT was statistically significant and
better than cVMAT and IMRT. As for the sparing of OARs, HT had a statistically significant
advantage in the Dmean and Dmax of the planning organ at risk volume of the brain stem, as it was
lower. The same applied to the lenses of the eyes. It was shown that there was a statistically
significant difference for which HT had reduced dose to the lenses when compared to cVMAT
and IMRT. There was a not a statistically significant difference between cVMAT and IMRT.
For the optic nerves, there was not a statistically significant difference between the three
planning modalities. Coplanar VMAT had the greatest reduction of the optic chiasm when
compared to HT and IMRT.9
When looking at hippocampus sparing during whole brain radiotherapy, one study
concludes that HT has a better homogeneity index for treatment in the brain when compared to
cVMAT and step and shoot IMRT. However, the time taken to deliver was significantly shorter
for VMAT when compared to HT (2.5 minutes compared to 18 minutes). The same study also
found that the dose to the eyes and lenses were statistically significantly different when
comparing HT to VMAT and IMRT. HT has lower doses for the lenses and globes of the eye.
The study discusses this may be due to the planning constraints use for VMAT and IMRT.15
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Previous studies show that nVMAT and HT seem to be the preferred option in many of
these cases.9,12–14 However, to the authors current knowledge, no studies compare nVMAT to
HT for centrally located brain tumors. Both nVMAT and HT have been proven to reduce doses
to OARs when compared with IMRT and cVMAT.9,12–14 HT also has been shown to increase the
CI and HI of the plans when compared to IMRT and VMAT.9,15
The purpose of the current study is to perform a dosimetric radiation treatment plan
evaluation in order to determine which radiation treatment modality (cVMAT, nVMAT, or HT)
has the highest conformity index and homogeneity index as well as the lowest mean dose and
lowest maximum dose for critical structures for centrally located brain tumors. This will allow
more appropriate modality decisions when deciding which modality to treat patients with
centrally located brain tumors. The researcher hypothesizes that HT will achieve better HI and
CI while at the same time having a lower dose to the OAR.
Null hypothesis (H0): There will not be a difference between homogeneity index,
conformity index, and dose to organs at risk when comparing helical tomotherapy, non-coplanar
VMAT, and coplanar VMAT.
Alternative hypothesis (Ha): There will be a difference between homogeneity index,
conformity index, and dose to organs at risk when comparing helical tomotherapy, non-coplanar
VMAT, and coplanar VMAT.

Materials and Methods
Subjects
This retrospective study was conducted using medical chart data from 10 patients who
had received radiation therapy to the brain. The study was completed in collaboration with a
medical center located in the midwestern United States. To be included in the study, all of the
7

subject’s diagnosis needed to include a parent grouping ICD 10 code of C71, which corresponds
to malignant neoplasms of the brain. The patient also had to have a centrally located brain tumor
where the CTV was within 5cm of the sella turcica.
A report was run in MOSAIQ (version 2.64) radiation oncology management system to
see which datasets were available and had the proper ICD 10 diagnosis code. Selection started
with the most recent patient who had completed radiotherapy and went backwards
chronologically to limit the number of charts reviewed for inclusion and exclusion criteria. In
order to make sure each patient had a centrally located brain tumor, during patient selection, each
set of contours for the subject was reviewed to make sure the clinical target volume was within 5
centimeters from the sella turcica. Demographics were reviewed to exclude subjects who were
pregnant women, prisoners, and 25 years old and younger at the time of their planning
simulation. Scans for re-irradiation and recurrent brain tumors were also excluded. Subjects who,
at the time of consent for radiation treatment, indicated that they did not want to participate in
research studies were excluded as well.
Ethical Considerations
All study protocol was reviewed and approved by the Midwest hospital’s institutional
review board. In addition, the study protocol was reviewed and approved by the first author’s
academic institutional review board. Patient names were genericized (Patient 1, Patient 2, etc)
prior to use within this study. Paper copies of medical chart documents were kept in a locked
file cabinet or locked office. After the paper documents were used, they were shredded using the
Midwest hospital system’s shredding bins. The integrity of digital data was kept secure in a
password secure OneDrive account associated with the Midwest hospital. A code for linking the
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data to the patient was kept in a password protected file in the Midwest hospital’s OneDrive per
institution policy.
Treatment planning
Previously completed datasets of each the subjects had the patient scanned in the supine
position, had used an aquaplast mask, and was scanned on the Philips Big Bore CT scanner with
2 mm for slice thickness. Scans started above the head and continued down below the fifth
cervical vertebrae. The contours for targets and normal structures were imported into the
Pinnacle treatment planning system (version 16.2.1) from the previously approved plans.
All of the plans were given the prescription of 54 Gy to PTV54 and 60Gy to PTV60 in 30
fractions using a simultaneous integrated boost. Both the cVMAT and nVMAT were planned on
the Pinnacle treatment planning system (version 16.2.1) using the autoplan feature. The HT plan
was done on the Accuray Precision (version 3.1.0.0) planning system. All plans were done by the
same planner.
For the cVMAT, two 6MV beams were planned for use on the Varian Truebeam at the
Midwest Hospital. Both beams use 354 degree arcs from 178 to 182 degrees and from 182 to
178 degrees with couch at 0 degrees. Collimator rotation was 30 degrees and 330 degrees
respectively. Equal weighting to the beams was applied before autoplanning was initiated.
Motion constraint was at .46 cm. The planning goal for the PTV was 1% higher than the
prescription dose due to Midwest Hospitals standard workflow. Final dose was calculated using
the CC convolution algorithm. See Table 1 for dose constraints to OARs used in all planning
modalities.
For nVMAT, three 6MV beams were planned for use on the Varian Truebeam at the
Midwest Hospital. The first beam was with the couch at 350 degrees and the arc from 178 to
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302 degrees. The second beam’s arc was from 182-62 degrees with the couch at 10 degrees. The
third beam’s arc was from 0 to 36 degrees with the couch at 270 degrees. Collimator angles were
30, 330, and 0 degrees respectively. Weighting was applied in proportion to arc length. The
autoplanning dose for the PTV was 1% higher than the prescription dose due to the standard
workflow of the Midwest Hospital. Motion constraint was at .46cm before initiating
autoplanning. Final dose was calculated using CC convolution algorithm.
The HT plans were planned with Accuray Precision version 3.1.0.0 planning software.
Field width was set at 2.5cm, pitch at .275, and the modulation factor was set at 2.2. Target dose
was set at 54 Gy to PTV 54 at 50% of the volume and 60Gy to the PTV60 at 50% of volume.
Both percentages moved up until 98% of PTV reached 95% of the prescription dose or higher in
accordance with the Midwest Hospital’s planning workflow for HT.
Plan coverage quality was evaluated by using Paddick’s Conformity Index (CI) and
homogeneity index (HI). Paddick’s CI was calculated by using the formula
PCI=(TVPIV)2/(TV*PIV) where TVPIV is the target volume covered by the prescription isodose
volume, TV is the Target Volume, and PIV is the prescription isodose volume.16 The closer the
number to 1, the more conformal and better the plan is considered to be.17 Homogeneity index is
calculated by using the formula HI= D95/D5, where D95 is the dose at 95% volume of the PTV
and D5 is the dose at 5% of the volume of the PTV.18 Plan quality was also compared using the
Dmax and Dmean values of the OARs.
Data Analysis
Variables were analyzed using one way repeated measure analysis of variance
(ANOVA) followed by Bonferroni post hoc test using SPSS statistical software (version
26.0.0.0) . CIs and HIs were compared as well as Dmax and Dmean values of the OARs. Statistical

10

significance was determined by p values less than 0.05. Mauchly’s test of sphericity was
conducted, and when applicable, Greenhouse-Geisser results were reported.

Results
The goal of this study was to compare and evaluate the differences between the planning
modalities of cVMAT, nVMAT, and HT for centrally located brain tumors. CI and HI were
evaluated for target coverage and dose maximums and means were evaluated for critical
structures. Descriptive statistics for the statistically significant values of CI and HI can be found
in Table 2 while the descriptive statistics for OARs with statistically significant maximum dose
differences can be found in Table 3. Table 4 shows the descriptive statistics for OARs with a
statistically significant mean dose difference. A summary of ANOVA results for can be found in
Table 5.
Target Volumes
For the CI for the 95% of the prescription dose to PTV 54 (5130 cGy), ANOVA was
found to be significant, F (2, 18) = 3.641, p = 0.047. No statistically significant reaction was
found between planning modalities during post hoc analysis.
In regards to CI of the prescription dose (5400 cGy) to PTV 54, ANOVA was found to be
significant, F (1.28, 11.523) = 5.949, p = 0.026. A significant reaction was found between
nVMAT and HT, p = 0.036. The mean difference was 11.1 % closer to 1 for nVMAT when
comparing HT to nVMAT.
Concerning the CI of 95% the prescription dose to PTV 60 (5700 cGy), ANOVA was
found to be significant, F (1.138, 10.24) = 20.11, p = 0.001. A significant reaction was found
between cVMAT and HT, p = 0.003, and nVMAT and HT, p = 0.005. The mean difference was
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21.5% closer to 1 for HT when comparing HT to cVMAT and 22.1 % closer to 1 for HT when
comparing nVMAT to HT.
For the HI of PTV 60, ANOVA was found to be significant, F (1.114, 10.026) = 5.703, p
= 0.035. No statistically significant reaction was found between planning modalities during post
hoc analysis. See Figure 2 for comparison of HI for PTV 54 and PTV 60.
Critical Structures and Organs at Risk
For the brain stem mean dose, ANOVA was significant, F (1.093, 9.836) = 7.69, p =
0.018. A significant reaction was found between cVMAT and HT, p = 0.047. The mean
difference was 334.16 cGy higher with HT.
In regards to the left lens maximum dose, ANOVA was found to be significant, F (1.188,
10.691) = 15.76, p = 0.002. A significant reaction was found between cVMAT and HT, p =
0.007, and nVMAT and HT, p = 0.009. The mean difference was 278.57 cGy higher for HT
when comparing HT to cVMAT and 309.48 cGy higher for HT when comparing nVMAT to HT.
Concerning the left optic nerve maximum dose, ANOVA was significant, F (1.245,
11.207) = 14.94, p = 0.002. A significant reaction was found between cVMAT and HT, p = 0.01,
and nVMAT and HT, p = 0.008. The mean difference was 1212.8 cGy higher for HT when
comparing HT to cVMAT and 1317.56 cGy higher for HT when comparing nVMAT to HT.
For the mean dose for the volume of the normal brain minus the volume of the PTV,
ANOVA was found to be significant, F (2, 18) = 14.77, p < 0.001. A significant reaction was
found between cVMAT and HT, p = 0.009, and nVMAT and HT, p = 0.008. The mean
difference was 475.49 cGy higher for HT when comparing HT to cVMAT and 400.7 cGy higher
for HT when comparing nVMAT to HT.
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In regards to the right cochlea mean dose, ANOVA was found to be significant, F (1.057,
9.515) = 5.645, p = 0.039. No statistically significant reaction was found between planning
modalities.
Concerning the right lens max dose, ANOVA was found to be significant, F (1.117,
10.049) = 8.396, p = 0.014. A significant reaction was found between cVMAT and HT, p =
0.028. The mean difference was 257.39 cGy higher for HT when comparing HT to cVMAT.
For the right optic nerve max dose, ANOVA was found to be significant, F (1.065, 9.584)
= 15.66, p = 0.003. A significant reaction was found between cVMAT and HT, p = 0.011, and
nVMAT and HT, p = 0.008. The mean difference was 1392.92 cGy higher for HT when
comparing HT to cVMAT and 1477.79 cGy higher for HT when comparing nVMAT to HT.

Discussion
In this study, maximum and mean dose values were compared for organs at risk while
Paddick’s conformity index as well as homogeneity index was compared for targets. Two
different planning systems were used to create the plans. For the nVMAT and cVMAT plans,
Pinnacle version 16.2.1 was used and for the HT, Precision version 3.1.0.0 was used. The
planning methods are different between the planning systems. There was a statistically
significant difference between a number of OARs, the CIs, and the HIs. This rejected the null
hypothesis because the data favored the alternative hypothesis. Some of the results of the study
were similar to previous literature and some was different.
One similarity to Hou’s research was that cVMAT and nVMAT did not affect OAR
doses between the two of those modalities.12 This study is also similar to Liu’s research in that
HT had better HI when compared to cVMAT but in this study, it was statistically significant for
PTV 60.9 HT showed some improvement for CI compared to cVMAT for 5700cGy and 6000
13

cGy, which was similar to Liu and Rong.9,15 HT did not provide lower dose to OARs in this
study like it did in Liu’s and Rong’s study.9,15
The differences between the HT and the VMAT plans for OARs may be attributed to the
difference in the planning systems as well as the end planning constraints for the plans. For the
HT plans, all the planning constraints were first set at the tolerance dose. After more than 100
iterations, constraints were lowered to bring the dose maximum’s down. If the doses were
significantly below tolerance, the constraint was not lowered again because the plan could have
potentially lost coverage. This is a large difference in between how Pinnacle autoplan operates.
For Pinnacle, it will bring the dose maximums and means below what is requested if the iterative
process can find a lower global minimum for the planning. This may account for many of the
differences where HT was statistically significantly higher when compared to nVMAT and
cVMAT, but neither of the VMAT plans were significant compared to each other.
Another large difference is the way the planning system deals with prescribed dose. For
Pinnacle, the way the Midwest Hospital plans is by prescribing 1% higher for the prescription
dose while for Precision, the prescription dose is started out getting prescribed to 50% of the
volume and slowly gets increased until 98% of the volume gets 95% of the prescription dose.
This may cause significant difference for the conformity index as well as the homogeneity index.
Limitations
Something that was not reflected in the results was the fact that some of the tumors
abutted certain critical structures such as the brainstem and optic chiasm. Most of the values that
did not meet constraints were close to tolerance, such as 5420 cGy whereas the tolerance was
5400 cGy. All dose constraints were able to be met on HT whereas on two patients (Patient 4 and
Patient 8) the brain stem constraints were violated on the cVMAT and nVMAT plans, averaging
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around 5700 cGy. This would not be acceptable for treatment. This was not able to be met
because of the proximity of the PTV60 to the brainstem in both cases. The brainstem was 3mm
away from PTV 60.
This limitation likely increased the conformity and homogeneity for the targets on the
nVMAT and cVMAT. While a physician may have approved the treatment plan for the doses
that were close to the 54 Gy, if the limit was increased to that maximum for the HT plans,
coverage may have been better on the HT plans. See Figure 1 to look at mean CI for all dose
planning levels. There are some organs where the physician would not have accepted above
tolerance dose. In this way, the plans for HT were better because they met all tolerance doses.
The conformity index and homogeneity index may have been better for the VMAT plans because
the dose to these structures were higher. This makes it very difficult to compare and figure out
which type of treatment modality may be better.
Even though all tumors were centrally located and the CTV was less than 5 cm away
from the sella turcica, some tumors were located more laterally. For these, HT was significant
below the tolerance dose at first run through, so it was not pushed as hard in Precision as it was
in autoplan on Pinnacle. For example, for patient 1, the optic chiasm averaged 550cGy for the
nVMAT and cVMAT plans whereas, the HT plan it was nearly 3 times that much at 1568cGy.
This is very far below tolerance (5400cGy) so it would not have necessarily been attempted to be
lowered. This was the case for all of the OARs that had a statistically significant difference
between the VMATs and HT but not between the cVMAT and nVMAT.
Another cause that may have led to the difference between OAR max doses could have
been the lack of experience of the treatment planner. Before starting to plan the HT plans, only
about 10 plans were completed using the Precision software whereas 60+ were completed using
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Pinnacle software. Another limitation of the study is that it was a small sample size with only 10
different datasets compared for each modality. A greater number of datasets should be studied in
the future for purpose of generalizability.

Conclusion
The purpose of the research was to determine which treatment modality (nVMAT,
cVMAT, or HT) had the highest CI and HI and lowest dose to organs as risk to see if there was a
clear benefit in treating with one modality over another. There were statistically significant
results so there is a link between planning modality and dose to OARs, CI, and HI for centrally
located brain tumors. For the conformity index of 5400cGy, nVMAT was better (closer to 1)
than HT by 11.1%. The conformity index of 95% of the prescription dose to PTV60 (5700cGy)
was significantly better for HT when compared to cVMAT and nVMAT (21.5% and 22.1%
closer to 1, respectively). For HI, there was not a significant reaction between the modalities
during post hoc testing. Further research could verify if the difference between the CI for the
low dose prescription (5400cGy) could be attributed to some of the plans on nVMAT and
cVMAT not being able to meet the constraints for the brainstem.
When looking at the max doses of organs at risk, the mean of the HT plans was
significantly higher in HT for the left lens, right lens, left optic nerve, and right optic nerve. HT
also had a higher mean dose for the brain stem mean dose and normal brain minus PTV mean
dose. HT met all dose maximums for all plans whereas nVMAT and cVMAT did not. Future
research should be done to see if pushing harder on OARs for HT that are far below tolerance
could benefit the patient without losing coverage and make the dose to the OARS not as
significant of a difference between treatment modalities. While all modalities have proven
acceptable and useful in treating centrally located brain tumors, treatment planners may want to
16

consider using HT first because it was able to meet all dose constraints while still achieving
acceptable PTV coverage.
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Table 1
Dose Constraints Used in Planning
Structure

Dmax (Gy)

Brainstem

54

Normal Brain Tissue-PTV

65

Dmean (Gy)

Right Cochlea

45

Left Cochlea

45

Right Lens of Eye

10

Left Lens of Eye

10

Optic Chiasm

54

Right Optic Nerve

54

Left Optic Nerve

54

Spinal Cord

50
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Table 2
Descriptive Statistics of Statistically Significant Conformity and Heterogeneity Indexes
Index and Level

Modality

Mean

Std Deviation

N

CI of 5130 cGy

cVMAT

1.048

0.459

10

nVMAT

1.228

0.608

10

HT

1.384

0.663

10

cVMAT

0.709

0.301

10

nVMAT

0.654

0.301

10

HT

0.544

0.267

10

cVMAT

0.465

0.133

10

nVMAT

0.459

0.136

10

HT

0.68

0.116

10

cVMAT

0.044

0.012

10

nVMAT

0.044

0.010

10

HT

0.06

0.018

10

CI of 5400 cGy

CI of 5700 cGy

HI of PTV 60 Gy
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Table 3
Descriptive Statistics for OARs with Statistically Significant Maximum Dose Differences
OAR

Modality

Mean (cGy)

Std Deviation

N

Left Lens

cVMAT

344.9

186.230

10

nVMAT

314

182.359

10

HT

623.5

277.378

10

cVMAT

2150.6

1673.707

10

nVMAT

2045.8

1675.267

10

HT

3363.4

1613.219

10

cVMAT

330.8

211.095

10

nVMAT

341.4

239.555

10

HT

588.2

262.836

10

cVMAT

2019.9

1892.634

10

nVMAT

1935

1885.363

10

HT

3412.8

1681.316

10

Left Optic Nerve

Right Lens

Right Optic Nerve
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Table 4
Descriptive Statistics for OARs with Statistically Significant Mean Dose Differences
OAR

Modality

Mean (cGy)

Std Deviation

N

Brain Stem

cVMAT

2900.14

1856.049

10

nVMAT

2882.74

1881.144

10

HT

3234.3

1710.749

10

cVMAT

1936.11

464.516

10

nVMAT

2010.89

415.518

10

HT

2411.6

635.002

10

cVMAT

1342.22

1321.207

10

nVMAT

1363.49

1242.673

10

HT

2016.5

1778.497

10

Normal Brain-PTV

Right Cochlea
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Table 5
ANOVA Summary Table for OARs, CI, and HI
Source

df

MS

F

p

Brain Stem Mean Dose

1.093

3005.7

7.69

0.018

Left Lens Max Dose

1.188

427.5

15.764

0.002

Left Optic Nerve Max Dose

1.245

2519.9

14.943

0.002

Normal Brain-PTV Mean Dose

2

2119.5

14.769

<0.001

Right Cochlea Mean Dose

1.057

1574.1

5.645

0.039

Right Lens Max Dose

1.117

420.1

8.396

0.014

Right Optic Nerve Max Dose

1.065

2455.9

15.658

0.003

CI of 5130 cGy

2

1.22

3.641

0.047

CI of 5400 cGy

1.28

0.636

5.949

0.026

CI of 5700 cGy

1.138

0.535

20.109

0.001

HI of PTV 60 Gy

1.114

0.049

5.703

0.035

NOTE: All doses reported in cGy
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Figure 1
Conformity Index Mean Values

2.25
2
1.75
1.5
1.25
1
0.75
0.5
0.25
0

cVMAT nVMAT

HT

cVMAT nVMAT

HT

cVMAT nVMAT

HT

cVMAT nVMAT

HT

5130 cGy 5130 cGy 5130 cGy 5400cGy 5400cGy 5400cGy 5700cGy 5700cGy 5700cGy 6000cGy 6000cGy 6000cGy

Note. Mean Paddick’s Conformity Index values are shown for the different planning modalities
(cVMAT, nVMAT, and HT) for different dose levels (5130 cGy, 5400 cGy, 5700 cGy, and 6000
cGy). The error bars show standard deviations. HT had the closest to 1 CI for target volumes
5700 cGy and 6000 cGy. The closest to 1 for 5130 cGy and 5400cGy were cVMAT.
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Figure 2
Homogeneity Index Mean Values
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Note. Mean homogeneity index values are shown for the different planning modalities (cVMAT,
nVMAT, and HT) for the 2 different PTVs (PTV 54 and PTV60). The error bars show standard
deviations.
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